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Abstract
Background: Reactive oxygen species (ROS) were shown to mediate aberrant contractility in hypertension, yet the
physiological roles of ROS in vascular smooth muscle contraction have remained elusive. This study aimed to
examine whether ROS regulate a1-adrenoceptor-activated contraction by altering myosin phosphatase activities.
Methods: Using endothelium-denuded rat tail artery (RTA) strips, effects of anti-oxidants on isometric force, ROS
production, phosphorylation of the 20-kDa myosin light chain (MLC20), and myosin phosphatase stimulated by
a1-adrenoceptor agonist phenylephrine were examined.
Results: An antioxidant, N-acetyl-L-cysteine (NAC), and two NADPH oxidase inhibitors, apocynin and VAS2870,
dose-dependently inhibited contraction activated by phenylephrine. Phenylephrine stimulated superoxide anion
production that was diminished by the pretreatment of apocynin, VAS2870, superoxide scavenger tiron or
mitochondria inhibitor rotenone, but not by xanthine oxidase inhibitor allopurinol or cyclooxygenase inhibitor
indomethacin. Concurrently, NADPH oxidase activity in RTA homogenates increased within 1 min upon
phenylephrine stimulation, sustained for 10 min, and was abolished by the co-treatment with apocynin, but not
allopurinol or rotenone. Phenylephrine-induced MLC20 phosphorylation was dose-dependently decreased by
apocynin. Furthermore, apocynin inhibited phenylephrine-stimulated RhoA translocation to plasma membrane and
phosphorylation of both myosin phosphatase regulatory subunit MYPT1
Thr855 and myosin phosphatase inhibitor
CPI-17
Thr38.
Conclusions: ROS, probably derived from NADPH oxidase and mitochondria, partially regulate a1-adrenoceptor-
activated smooth muscle contraction by altering myosin phosphatase-mediated MLC20 phosphorylation through
both RhoA/Rho kinase- and CPI-17-dependent pathways.
Background
Excessive production of reactive oxygen species (ROS)
causes oxidative stress, which represents an important
mechanism in the pathogenesis of vascular diseases such
as hypertension and atherosclerosis. However, ROS act
as intracellular signaling molecules mediating various
cellular functions including proliferation, apoptosis and
survival [1]. Emerging evidence also indicated that ROS
can regulate vasoconstriction or vasodilatation depend-
ing on the vascular bed studied and oxygen radicals
formed [2]. Superoxide anion (·O2
-)w a ss h o w nt o
mediate hypertension induced by vasoactive factors such
as angiotensin II [3,4] and endothelin [5] or by deoxy-
corticosterone acetate-salt [6]. In addition, superoxide
anion amplifies allergen-induced airway hypercontracti-
lity [7]. How superoxide anion accomplishes these
effects remains poorly understood.
In the vasculature, the potential sources of ROS
include NADPH oxidase, uncoupled endothelial nitric
oxide synthase, xanthine oxidase, cyclooxygenase and
the mitochondrial respiratory chain. Among these,
NADPH oxidase is generally considered the major
source of vascular ROS [8] and has been shown to regu-
late myogenic constriction [9] and endothelin 1-acti-
vated vascular tone [10]. However, a recent study
suggested that mitochondria-derived, not NADPH
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vasoconstriction [11].
Phosphorylation of the 20-kDa myosin light chains
(MLC20) is a key determinant for smooth muscle con-
traction. The levels of MLC20 phosphorylation are deter-
mined by the activity ratio between myosin light chain
kinase (MLCK) and myosin phosphatase. While MLCK
activation depends on the cytoplasmic calcium concen-
tration, myosin phosphatase activity is subject to the
modulation by various signaling molecules [12]. Myosin
phosphatase is a heterotrimer consisting of a 37- to 38-
kDa catalytic subunit, PP1δ, a 110- to 130-kDa regula-
tory subunit referred to as myosin phosphatase targeting
subunit 1 (MYPT1), and a 20-kDa subunit. Multiple
vasoconstrictors inhibit myosin phosphatase activities
through the phosphorylation of MYPT1 and/or an
endogenous myosin phosphatase inhibitor CPI-17 [13].
In vivo evidence showed that Rho kinase plays impor-
tant roles in MYPT1 phosphorylation whereas protein
kinase C catalyzes CPI-17 phosphorylation [13,14].
Recent evidence indicated that ROS mediate a1-adre-
noceptor-stimulated hypertrophy of vascular smooth
muscle and cardiomyocytes, a long-term effect of cate-
cholamines [15-17]. Currently, the contribution of ROS
to the acute vasoconstrictor effect of a1-adrenoceptors
has not been characterized. ROS generated exogeneously
by xanthine oxidase activate Rho/Rho kinase-mediated
Ca
2+ sensitization pathway to contract rat aorta [18].
Our previous study showed that a1-adrenoceptor stimu-
lation activates Rho kinase-mediated MYPT1 phosphor-
ylation and protein kinase C-mediated CPI-17
phosphorylation to regulate vasoconstriction [19].
Whether ROS regulate vasoconstrictors-activated con-
tractile force and MLC20 phosphorylation by altering
myosin phosphatase activities remains unclear. There-
fore, this study investigated whether a1-adrenoceptor
activation triggers ROS formation to regulate contrac-
tion through altering myosin phosphatase activity.
Materials and methods
Tissue preparation and isometric force measurement
This study conforms to the procedures described in the
Guide for the Care and Use of Laboratory Animals of the
National Institute of Health (U. S. A.), and the experi-
mental procedures were approved by the institutional
Animal Care and Use Committee. Male Sprague-Dawley
rats weighing 400 ~ 550 g were used in this study. After
the animal was anesthetized with pentobarbital (60 mg
kg
-1, i.p.), the tail artery was removed and placed in oxy-
genated (95% O2 -5 %C O 2)K r e b s ’ physiological salt
solution (PSS) with the following composition (in mM):
120 NaCl, 5.9 KCl, 25 NaHCO3,1 . 2N a H 2PO4,1 1 . 5d e x -
trose, 1.2 MgCl2 and 2.5 CaCl2 .T h ee n d o t h e l i u m -
denuded rat tail artery (RTA) strips were placed in tissue
bathes with one end held in a muscle holder and the
other end connected to a force transducer. After being
stretched to the length that allows for maximal force pro-
duction and being equilibrated at 37°C for at least 1 h,
muscle strips were stimulated twice with 51 mM KCl-
PSS (equimolar replacement of NaCl with KCl) to
generate reproducible contraction. A dose response was
generated with cumulative concentrations of a1-adreno-
ceptor agonist phenylephrine and the maximal force was
used to normalize later contractile responses. To deter-
mine the involvement of ROS and NAD(P)H oxidase,
tissues were incubated for 30 min in PSS containing vehi-
cle, N-acetyl-L-cysteine (NAC), apocynin or VAS2870.
A cumulative concentration-response for phenylephrine
was then performed again. In all other experiments,
10 μM phenylephrine was used.
Measurement of superoxide anion production
Superoxide production in RTA strips was measured by a
lucigenin-enhanced chemiluminescence assay according to
a published method [20]. RTA strips 10 mm long were
equilibrated in modified PSS-HEPES buffer (in mM: 119
NaCl, 20 HEPES, 4.6 KCl, 1 MgSO4,0 . 1 5N a 2HPO4,0 . 4
KH2PO4,5N a H C O 3, 5.5 glucose, 1.2 CaCl2,p H 7 . 4 )a t
37°C for 30~60 min. After equilibration, RTA strips were
incubated for 30 min in prewarmed PSS-HEPES buffer
containing 10 mM DETC (Sigma) in the presence or
absence of inhibitors for superoxide generation. DETC was
used to inhibit the endogenous Cu
2+/Zn
2+ superoxide dis-
mutase (SOD) activity. Following DETC treatment, RTA
strips were placed in temperature-controlled (37 °C) sam-
ple dishes containing 2 ml HEPES buffer with lucigenin
(20 μM, Sigma) plus or minus inhibitors and placed in the
dark chamber of the Chemiluminescence Analyzing Sys-
tem (Tohoku Electronic Industrial Co., Japan). The back-
ground counts were measured for 5 min, phenylephrine in
100 μl HEPES buffer was then injected into the chamber
and the chemiluminescence was measured for another
10 min. Lucigenin chemiluminescence was expressed as
counts per min (cpm) per milligram tissue weight after
subtracting background counts (without vessel).
Measurement of Vascular NAD(P)H Oxidase activity
RTA strips were stimulated with phenylephrine, snap-
frozen in liquid nitrogen at designated time points, and
stored at - 80 °C until use. NAD(P)H oxidase activity
was assayed according to a published method [21].
Briefly, RTA strips were homogenized on ice with a
glass-to-glass homogenizer for 2 min in phosphate
buffer (20 mM K2HPO4,p H7 . 4 ,1 0μgm l
-1 aprotinin,
10 μgm l
-1 leupeptin, and 0.5 mM phenylmethylsulfonyl
fluoride). Following 10-min centrifugation at 1,000 g,
supernatant (30-40 μl) was mixed with reaction buffer
containing (in mM) 37 NaCl, 2.7 KCl, 4.3 Na2HPO4,
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The reaction was started by the addition of NADPH
(300 μM, Sigma) and photon emission was measured for
10 min at room temperature in a scintillation counter
(LS-6500, Beckman) in out-of-coincidence mode.
NADPH oxidase activity was expressed as cpm per
microgram protein. The specificity of lucigenin for ·O2
-
production was validated by adding a nonenzymatic
scavenger of ·O2
-,t i r o n( 1 0m M ,S i g m a ) ,t oq u e n c ht h e
signal. To examine the effects of inhibitors, 1 mM
apocynin, 10 μM VAS2870, 100 μM allopurinol, 10 μM
rotenone or vehicle was added 30 min before RTA strips
were stimulated with phenylephrine for 1 min.
Measurement of MLC20 phosphorylation
MLC20 phosphorylation was measured by two-dimen-
sional polyacrylamide gel electrophoresis (PAGE) as pre-
viously described [19]. Briefly, homogenates of RTA
strips were sequentially resolved by isoelectric focusing
gel electrophoresis (Pharmalytes of 80% pH 4.5-5.4 and
20% pH 3-10, Amersham Pharmacia Biotech) in the first
dimension and SDS-PAGE in the second dimension.
The gels were silver stained and analyzed by densitome-
try. Data are expressed as the ratio of phosphorylated
MLC20 over total (phosphorylated plus unphosphory-
lated) MLC20.
Western blot analysis of MYPT-1 and CPI-17
phosphorylation levels
Equal amounts of protein were resolved under reducing
conditions on 8% SDS-PAGE (for MYPT1) or 12.5%
SDS-PAGE (for CPI-17) and transferred electrically onto
nitrocellulose membranes. Following 1.5 h blocking in a
Tris-buffered saline (TBS) solution containing 3% nonfat
dry milk at room temperature, membranes were incu-
bated overnight at 4°C with phosphospecific anti-
MYPT1
Thr697 or anti-MYPT1
Thr855 antibody (1:1000,
Upstate) or anti-CPI-17
Thr38 antibody (1:500, Upstate).
The blots were washed and incubated with horseradish
peroxidase-conjugated anti-rabbit IgG (1:5000, Chemi-
con) for 1.5 h at room temperature. Immunoreactive
bands were visualized by enhanced chemiluminescence
(PerkinElmer Life Sciences). Membranes were then
stripped of bound antibodies by incubation in a buffer
containing 62.5 mM Tris-HCl (pH 6.8), 2% SDS, and
10 mM DTT for 30 min at 50°C with agitation. The
blots were reprobed with anti-MYPT1 (1:7500, Covance)
or anti-CPI-17 (1:2000, Upstate) for loading control.
RhoA translocation assay
Translocation of RhoA from the cytosol to membrane
fractions was determined according to a published
method [22] with modifications. RTA strips stimulated
with phenylephrine for 1 min or 15 min with or without
inhibitors were snap frozen in liquid nitrogen. After
RTA strips were homogenized in ice-cold buffer
(in mM: 50 HEPES, pH 7.5, 50 NaCl, 1 MgCl2, 2 EDTA,
10 μgm l
-1 aprotinin and leupeptin, 1 phenylmethylsul-
fonyl fluoride, 50 sodium orthovanadate, 10 pyropho-
sphate, 10 NaF), the homogenates were centrifuged at
100,000 g, 4 °C for 30 min (Beckman Optima TLX
Ultracentrifuge, TLA 120.2 rotor). The supernatant was
collected as cytosolic fraction, and membrane proteins
were extracted by incubating the pellet for 30 min in
homogenization buffer containing 1% Triton X-100 and
0.25% sodium cholate. The extract was clarified at 800 g
for 10 min, and the supernatant was collected as the
particulate fraction. Protein concentrations were deter-
mined with a bicinchoninic acid kit (Pierce). Equal
amounts of protein were electrophoresed on 12.5% SDS-
PAGE followed by immunoblotting with a monoclonal
anti-RhoA antibody (1:500, Santa Cruz). The result was
expressed as the ratio of membrane RhoA/total RhoA
(membrane RhoA + cytosolic RhoA).
Statistical Analysis
Data were expressed as means ± SEM. For multiple
comparisons, ANOVA followed by Newman-Kuels or
Dunnett’s post-hoc test was used (Prism 4.0; GraphPad
Software, San Diego, CA). An unpaired Student’s t test
was used for comparison between control and treatment
group. P-values less than 0.05 were considered statisti-
cally significant.
Results
Antioxidant and NADPH oxidase inhibitors decrease
phenylephrine-induced force
The involvement of ROS in a1-adrenoceptor-activated
contraction was assessed by the effects of an antioxidant
and two NAD(P)H oxidase inhibitors on phenylephrine-
stimulated isometric force of RTA strips. As shown in
Figure 1, pretreating RTA with antioxidant NAC (A) or
NAD(P)H oxidase inhibitors, apocynin (0.3-3 mM, B)
and VAS2870 (1-10 μM, C), caused a rightward shift of
the concentration-response curve and reduced the maxi-
mal force to phenylephrine. These results suggested that
ROS, possibly derived from NADPH oxidase, are
involved in phenylephrine-activated contraction.
Phenylephrine stimulates ROS generation in RTA
We next examined whether phenylephrine stimulated ROS
production in RTA strips using lucigenin-enhanced chemi-
luminescence assay. As shown in Figure 2, phenylephrine
significantly increased chemiluminescence signals com-
pared to those of non-stimulated control (1611 ± 125.9
cpm mg tissue
-1 vs. 464.3 ± 58.8 cpm mg tissue
-1, p <0 . 0 5 ) .
Pretreatment with a selective a1-adrenoceptor antagonist
prazosin (1 μM) nearly abolished phenylephrine-stimulated
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-1)a n d
contractile response (data not shown). This result indicated
that phenylephrine stimulates superoxide production in a1-
adrenoceptor-dependent manner. To further unravel
sources for phenylephrine-stimulated superoxide anions,
we examined the effect of inhibitors for various ROS gen-
eration systems. Phenylephrine-induced ·O2
- production
was inhibited by the pretreatment with NAD(P)H oxidase
inhibitors apocynin (1 mM) and VAS2870 (10 μM), a
superoxide scavenger tiron (10 mM), and mitochondria
respiratory chain inhibitor rotenone (10 μM). In contrast,
xanthine oxidase inhibitor allopurinol (100 μM) and
cyclooxygenase inhibitor indomethacin (10 μM) had no
effect. These results suggested that NAD(P)H oxidase and
mitochondria, but not xanthine oxidase or cyclooxygenase,
may contribute to phenylephrine-stimulated superoxide
production.
The role of NAD(P)H oxidase in phenylephrine-
induced superoxide production was further corroborated
by activity assay in RTA homogenates. We tested both
NADH and NADPH as the substrate for activity assay
and found that 300 μM NADPH, but not NADH,
elicited detectable signals. As shown in Figure 3A, acti-
vation of NAD(P)H oxidase occurred within 1 min upon
phenylephrine stimulation and persisted for at least
Figure 1 Effects of NAC (a), apocynin (b) and VAS2870 (c) on
phenylephrine-induced contraction of RTA strips. Two
cumulative concentration-responses were constructed in RTA strips
stimulated with a1-adrenoceptor agonist phenylephrine. For the
second contraction, RTA strips were preincubated for 30 min with
NAC (10~20 mM), apocynin (0.3~3 mM), VAS2870 (1~10 μM) or
vehicle, then were stimulated with agonist in the continuous
presence of the inhibitor. Data are mean ± S.E.M. of 6 independent
experiments. Force is expressed as the percentage of maximal force
obtained in the first contraction.
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Figure 2 Phenylephrine-stimulated superoxide anion
generation. RTA strips were stimulated with 10 μM phenylephrine
and superoxide anion generation was measured by lucigenin-
enhanced chemiluminescence as described in Methods. Some
vessels were incubated for 1 hr with a1-adrenoceptor antagonist
prazosin (1 μM) or for 30 min with VAS2870 (10 μM), apocynin (1
mM), tiron (10 mM), indomethacin (10 μM), allopurinol (100 μM),
rotenone (10 μM) or vehicle (DMSO or ethanol) before and during
phenylephrine treatment. As the values obtained in the presence of
DMSO or ethanol were not different from that of phenylephrine
alone, the data were pooled. Each bar represents mean ± S.E.M. of
six to ten independent experiments. *p < 0.001 vs. control;
#p < 0.05 vs. vehicle.
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-1 for control, 179 ± 5
and 217 ± 32 cpm μgp r o t e i n
-1 for 1-min and 10-min
phenylephrine stimulation, respectively, p <0 . 0 5c o m -
pared to control). As shown in Figure 3B, apocynin
(1 mM) effectively reduced phenylephrine-stimulated
chemiluminescence at 1 min (185 ± 14 cpm μgp r o t e i n
-
1 for vehicle control, 86 ± 16 cpm μg protein
-1 for apoc-
ynin; p < 0.05). In contrast, neither allopurinol (100 μM)
nor rotenone (10 μM) exhibited significant inhibition.
These results implied that NAD(P)H oxidase is involved
in phenylephrine-stimulated superoxide anion produc-
tion in RTA strips.
ROS regulate phenylephrine-stimulated MLC20
phosphorylation
To determine whether ROS are involved in regulating
phenylephrine-activated MLC20 phosphorylation, we
measured MLC20 phosphorylation levels in the presence
and absence of apocynin. As depicted in Figure 4A, at
1-min phenylephrine stimulation, MLC20 phosphoryla-
tion increased markedly from 10 ± 1.1% to 43 ± 1.2%
(p < 0.001), pretreatment of apocynin (1.5 or 3 mM)
dose-dependently inhibited phenylephrine-stimulated
MLC20 phosphorylation. Similarly, at 15-min phenylephr-
ine stimulation, MLC20 phosphorylation was inhibited by
apocynin in a dose-dependent manner (p < 0.05, Figure
4B). These results suggest that ROS modulate pheny-
lephrine-stimulated MLC20 phosphorylation.
Figure 3 NADPH oxidase activation in response to
phenylephrine stimulation. (a) Time course. RTA strips were
stimulated with 10 μM PE for the indicated period. NADPH oxidase
activity was measured in RTA homogenates as described in
Methods and was expressed as mean ± SEM of 5 independent
experiments. *P< 0.05 vs. unstimulated control. (b) Effects of pro-
oxidative enzyme inhibitors. RTA strips were incubated for 30 min
with the indicated inhibitors, followed by 1-min phenylephrine
stimulation. Results were expressed as mean ± S.E.M. of 6~8
independent experiments. *P < 0.05 vs. unstimulated control; #p <
0.01 vs. phenylephrine alone.
Figure 4 Effects of apocynin on phenylephrine-induced MLC20
phosphorylation. RTA strips were pretreated for 30 min with
apocynin or vehicle, followed by phenylephrine stimulation. Tissues
were snap-frozen at 1 min (a) or 15 min (b). MLC20 phosphorylation
was analyzed by 2-D PAGE as described in Methods. Results are
expressed as mean ± S.E.M. from 5~9 independent experiments.
Apo: apocynin. * p < 0.01 vs. resting control;
# p< 0.05 vs.
phenylephrine alone.
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phosphorylation
To elucidate whether ROS affect MLC20 phosphoryla-
tion through inhibiting myosin phosphatase, MYPT1
phosphorylation levels at two regulatory sites, Thr697
and Thr855, were examined. As shown in Figure
5 B ,w i t h i n1m i no fp h e n y l e p h r i n es t i m u l a t i o n ,
MYPT1
Thr855 phosphorylation increased approximately
2-fold and was eliminated with apocynin pretreatment.
At 15 min, phenylephrine caused a small but significant
increase in MYPT1
Thr855 phosphorylation, which was
attenuated by apocynin. In contrast to MYPT1
Thr855
phosphorylation, no change was detected in
MYPT1
Thr697 phosphorylation in response to pheny-
lephrine or apocynin (Figure 5A).
ROS regulate phenylephrine-induced RhoA translocation
Since phenylephrine-stimulated MYPT1
Thr855 phosphor-
ylation is Rho kinase-dependent [19], the effects of sup-
pressing ROS generation on phenylephrine-induced
RhoA activation were examined by translocation assay.
As illustrated in Figure 6A, the fraction of membrane
RhoA (membrane RhoA/total RhoA) in the resting state
was 32 ± 4.5% and rapidly increased to 48 ± 4.0% at 1
min after phenylephrine stimulation (p <0 . 0 5 ,n =6 ) .
Pretreatment of RTA with apocynin abolished pheny-
lephrine-induced RhoA translocation (32 ± 4.4% for
apocynin, p < 0.05 compared to phenylephrine alone, n
= 6). Similar results were obtained at 15-min pheny-
lephrine stimulation (Figure 6B). The results of Figure 5
a n d6s u g g e s tt h a tR O Sa r ei n v o l v e di na1-adrenocep-
tor-stimulated RhoA/Rho kinase activation.
ROS regulate phenylephrine-stimulated CPI-17
phosphorylation
Our previous results showed that phenylephrine stimu-
lated CPI-17
Thr38 phosphorylation at the initial phase of
contraction in RTA strips [19]. Therefore, we examined
whether ROS regulate myosin phosphatase activity
through CPI-17
Thr38 phosphorylation. As shown in Fig-
ure 7, CPI-17
Thr38 phosphorylation at 1 min of pheny-
lephrine stimulation was markedly inhibited by apocynin
pretreatment. This result suggests that CPI-17 phos-
phorylation also provides a mechanism for ROS to regu-
late myosin phosphatase activity during a1-adrenoceptor
activation.
Discussion
Results of this study show that a1-adrenoceptor activa-
tion induced ROS (probably ·O2
-) production to regulate
vasoconstriction. While inhibition of xanthine oxidase
or cyclooxygenase did not affect ROS production in
phenylephrine-stimulated RTA, two structurally distinct
Figure 5 Effects of apocynin on phenylephrine-induced MYPT1
phosphorylation. RTA strips were pre-incubated with apocynin or
vehicle for 30 min and then challenged with phenylephrine for 1 or
15 min. Phosphorylation levels of MYPT1 at Thr697 (a) and Thr855
(b) were assessed by immunoblotting using phospho-specific
MYPT1 antibody. Equal protein loading was verified by total MYPT1
immunoreactivity. The upper panels show representative
immunoblots and the lower panels summarize the densitometric
results. Values were normalized against control and data are
presented as mean ± S.E.M. of four independent experiments. *p <
0.05 vs. control; #p < 0.05 compared with time-matched
phenylephrine alone.
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Our results also indicated that phenylephrine-activated
contractile response in RTA is only partially regulated
by ROS because apocynin and VAS2870, at concentra-
tions that attenuated 50~80% of ROS production, only
decreased force by 30%~40%.
Our results showed that a1-adrenoceptor activation
upon phenylephrine challenging increased ROS produc-
tion. What is responsible for a1-adrenoceptor-mediated
vascular ROS generation? Xanthine oxidase and cyclo-
oxygenase can be excluded since inhibiton of either
enzyme had no effect on phenylephrine-induced ROS
f o r m a t i o n .O n ep r o b a b l es o u r c ei sN A D P Ho x i d a s e .
Our finding that phenylephrine-induced ROS produc-
tion was attenuated by apocynin or VAS2870 pretreat-
ment supports this notion. Furthermore, phenylephrine
stimulation increased NADPH oxidase activity in RTA
homogenate, which was abolished by apocynin. For
more than a decade, apocynin has been used as a speci-
fic inhibitor to explore the role of NADPH oxidase in
the field of vascular biology. However, Heumueller et al
recently reported that apocynin is not an inhibitor of
vascular NADPH oxidase and instead acts as an antioxi-
dant, thereby reducing ROS bioavailability [23]. These
authors found that in the presence of myeloperoxidase
(MPO), apocynin is oxidized to form active dimers cap-
able of blocking the assembly and activation of NADPH
Figure 6 Effects of apocynin on phenylephrine-induced RhoA
membrane translocation. RTA strips were pre-incubated with
apocynin or vehicle for 30 min and then challenged with
phenylephrine for 1 min (a) or 15 min (b). The cytosolic and
membrane fractions were separated by ultracentrifugation and
RhoA in each fraction were analyzed by immunoblotting as
described in Methods. The top panels show representative
immunoblots. The bottom panels summarize the quantitative
results, expressed as the ratio of membrane RhoA to total RhoA,
from six independent experiments. The bars represent means ± S.E.
M.. *p < 0.05 vs. control;
#p < 0.05 vs. phenylephrine alone.
Figure 7 Effects of apocynin on phenylephrine-induced CPI-17
phosphorylation. RTA strips were incubated with apocynin (3 mM)
or vehicle for 30 min and then stimulated with phenylephrine for 1
min. The tissue was snap-frozen and CPI-17 phosphorylation was
assessed with CPI-17
Thr38 phospho-specific antibody. Equal protein
loading was verified by reprobing for total CPI-17 immunoreactivity.
The top panel shows the representative blots of phospho-CPI-
17
Thr38 and total CPI-17. The bottom panel summarizes the
densitometric results. The phosphorylation levels of CPI-17 were
quantified as the ratio of phosphorylated CPI-17 to total CPI-17
protein. The bars represent means ± S.E.M. of 9 experiments.
*p < 0.05 vs. control;
#p < 0.05 vs. phenylephrine alone.
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MPO, apocynin may not form active dimers and hence
can not block NADPH oxidase activation. Regardless of
mechanisms acted by apocynin, a novel NADPH oxidase
inhibitor, VAS2870 [24], inhibited phenylephrine-acti-
vated force and superoxide production by ~30% in RTA
strips. Taken together, NADPH oxidase-derived ROS
are likely to be involved in a1-adrenoceptor-activated
vasoconstriction.
Mitochondria present another likely source for a1-
adrenoceptor-induced ROS generation. An inhibitor of
mitochondrial respiratory chain, rotenone, markedly
decreased phenylephrine-induced ROS formation. This
finding is in good agreement with a previous study
showing that mitochondria are a major source of ROS
in response to phenylephrine stimulation in rat mesen-
teric artery [11]. Using mitochondria-selective ROS sca-
venger and fluorescent probe, the authors provide
convincing evidence to support the essential role of
mitochondria-derived ROS in the maintenance of a1-
adrenergic-dependent vasoconstriction [11]. Another
study by Bailey et al also reported that mitochondria-
derived ROS in smooth musclei n i t i a t ec o l d - i n d u c e d
constriction of cutaneous arteries [25]. Further
experiments are needed to elucidate the underlying
mechanisms for mitochondria-derived ROS to regulate
a1-adrenergic-activated vasoconstriction.
Myosin light chain phosphorylation levels are deter-
mined by the activity ratio between myosin light chain
kinase and myosin phosphatase. Phosphorylation of
MYPT1 inhibits myosin phosphatase activity, resulting
in increased MLC20 phosphorylation and smooth muscle
contraction [26,27]. Results of this study showed that at
initial phase a1-adrenoceptor stimulation activates NAD
(P)H oxidase with concomitant increases in RhoA trans-
location, MYPT1
Thr855 and MLC20 phosphorylation.
Apocynin at concentrations that abolished increase in
ROS production eliminated RhoA translocation and
MYPT1
Thr855 phosphorylation and decreased MLC20
phosphorylation. These results are consistent with the
idea that ROS play upstream signaling roles in RhoA/
Rho kinase activation and myosin phosphatase inhibi-
tion. At sustained phase, similar results were obtained
with apocynin on RhoA translocation, MYPT1
Thr855
phosphorylation and MLC20 phosphorylation. These
results suggest that ROS may regulate a1-adrenoceptor-
stimulated contraction through RhoA/Rho kinase-
mediated myosin phosphatase inhibition and thereby
increasing MLC20 phosphorylation. It was previously
reported that exogenously generated ·O2
- activates Rho/
Rho kinase pathway to promote contraction [18]. Knock
et al. recently showed that LY83583-generated super-
oxide activates Rho kinase-mediated phosphorylation
of MYPT1
Thr855, resulting in enhanced MLC20
phosphorylation and contraction in rat pulmonary
arteries [28]. Up to date, superoxide-dependent Rho/
Rho kinase activation in the artery under physiological
conditions has only been documented in chronic angio-
tensin II-induced hypertensive rats [29]. Results of this
study provide the first evidence indicating that ROS-
mediated RhoA activation occurs under the activation of
vasoconstrictor receptors. In this context, RhoA was
recently reported to be directly activated by ROS
through a redox-sensitive motif involving two cysteines
within the phosphoryl binding loop [30], a redox-active
domain present in most Rho GTPases [31].
Phosphorylation of CPI-17, a smooth muscle-specific
protein inhibitor of myosin phosphatase, by PKC pre-
sents another important mechanism to inhibit myosin
phosphatase activity [32,33]. It was shown that PKC iso-
forms, including a, bI, g, δ, ε, and ζ are activated by tyr-
osine phosphorylation, which can be regulated by
protein-tyrosine phosphatases (PTP) [34]. As PTP are
well-established targets of ROS [35], inhibition of PTP
by ROS can enhance PKC- and CPI-17-mediated inhibi-
tion of myosin phosphatase, resulting in increased
MLC20 phosphorylation and smooth muscle contraction.
The result that a1-adrenoceptor-induced CPI-17 phos-
phorylation was inhibited by apocynin suggested that
CPI-17-mediated myosin phosphatase inhibition pro-
vides another mechanism accounting for ROS actions.
Interestingly, apocynin was recently reported to inhibit
Rho kinase without involving vascular NAD(P)H oxidase
[36]. Our result that apocynin inhibited both Rho
kinase-dependent MYPT-1 phosphorylation and protein
kinase C-dependent CPI-17 phosphorylation strongly
suggested that apocynin acts as an antioxidant to inhibit
RhoA/Rho kinase and protein kinase C.
In addition to modulating myosin phosphatase activity,
ROS modulate intracellular Ca
2+ mobilization [37]. It
was reported that ROS increase cytoplasmic Ca
2+ by
inhibiting Ca
2+-ATPase activity and by promoting inosi-
tol trisphosphate-induced Ca
2+ release [38]. A recent
report illustrated that a functional NAD(P)H oxidase
system exists in the sarcoplasmic reticulum of coronary
artery smooth muscle, which produces ·O2
- locally to
regulate ryanodine receptor activity and Ca
2+ release
from sarcoplasmic reticulum [39]. Whether ROS also
increase MLC20 phosphorylation via the activation of
MLCK remains to be examined.
In summary, the present study showed that a1-adre-
noceptor-activated smooth muscle contraction is
modulated by ROS generation. Alpha1 adrenoceptor-
stimulated increases in ROS production, acting through
RhoA/Rho kinase-mediated MYPT1
Thr855 phosphoryla-
tion and Rho kinase-independent CPI-17
Thr38 phosphor-
ylation, lead to myosin phosphatase inhibition, MLC20
phosphorylation, and smooth muscle contraction.
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